Phase I study of MGY825 in patients with lung cancer
CMGY825A12101
Phase 1 other active
Quick answer
Phase I study of MGY825 in patients with lung cancer for Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
- Phase
- Phase 1
- Modality
- other
- Status
- active